Mutagenesis and directed evolution
When a strain or an enzyme is the limit of a process, changing the conditions around it eventually stops helping. Mutagenesis changes the catalyst itself — randomly, rationally, or both — and the screening behind it decides whether you find the variant that matters.
Talk to us about your enzymeWhat mutagenesis is asked to fix
We work on the genetic engineering and modification of microorganisms and enzymes to improve their activity and their properties. These are the three bottlenecks it is usually brought in for.
A yield that will not move
The biotransformation works and the number stays where it is. Process conditions have a ceiling; a better variant is what raises it.
A side activity or an inhibition
A by-product that costs you downstream, or a substrate or product that shuts the reaction down before the loading is economical. Both are properties of the catalyst, and both can be engineered out.
Performance under your conditions
Temperature, pH, solvent or matrix the wild type was never selected for. Selection is run under the conditions the process actually uses, not the ones the enzyme prefers.
How a project runs
Three stages, each ending in a decision rather than a report. How long each takes depends on how measurable the target property is — we size it after the first conversation, not before.
Proof of concept
The target property is defined and, more importantly, made measurable. We build the screening assay first — a high-throughput readout that correlates with what the process needs — because a library is only ever as good as the screen behind it.
Optimisation
Random mutagenesis where the structure–function relationship is unclear, rational and bioinformatics-guided design where it is not, and usually both in sequence. Large numbers of mutants are screened in parallel and the hits are re-measured against the same baseline before anyone calls them hits.
Industrialisation
The best variants are produced at scale, characterised properly and tested in the real process rather than in the screening format. Genetic stability and reproducibility are verified before a variant becomes the one you depend on.
What we measure
A better enzyme is a claim until the same assay says so twice. These are the endpoints we report.
- Activity — units per milligram against the parent, under the same assay
- Selectivity — regio-, stereo- and chemoselectivity, and the by-products removed or created
- Substrate and product inhibition — the loading ceiling before and after
- Operating window — temperature, pH and solvent tolerance of the variant against the parent
- Stability — activity retained over time and over cycles under process conditions
- Expression — because a better enzyme that expresses badly is not a better process
- Genetic stability — the improvement held over generations, not measured once on a fresh vial
- Performance in the real process — the number that decides, measured outside the screening format
The laboratory behind it
Equipment
| Molecular biology | Extraction, PCR and qPCR, cloning and vector construction, sequence verification and sequencing, up to the whole genome where needed |
| Culture | Shake flasks and deep-well for screening, bench bioreactors; CHO cell culture, from screening formats up to the 100-litre scale |
| Storage | Cryopreservation and storage at −80 °C, with identity, viability and purity checks on every bank |
| Analytics | SDS-PAGE, SEC, Bradford, HPLC and UPLC, activity assays according to the target |
What you take away
| Variant | The improved strain or enzyme, characterised and with its performance documented |
| Dossier | Data, conditions tested and results, in the form your technical file needs |
| Pilot batch | Production at scale when the project reaches that point |
Start with the bottleneck
Tell us which property is limiting the process today and how it is measured. We will tell you whether mutagenesis is the right route and what the first stage would look like.
Talk to us about your enzyme